|Bid||65.76 x 1300|
|Ask||66.57 x 1000|
|Day's Range||64.42 - 66.15|
|52 Week Range||53.79 - 84.84|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||30.58|
|Earnings Date||Feb 07, 2024 - Feb 12, 2024|
|Forward Dividend & Yield||0.20 (0.30%)|
|Ex-Dividend Date||Nov 30, 2023|
|1y Target Est||70.00|
Subscribe to Yahoo Finance Plus to view Fair Value for BRKR
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics' Arc™ system, an innovative, automated positive blood culture sample preparation platform, with Bruker's MALDI Biotyper® s